Awaiting development: Guidance and quality standards

Showing 11 to 20 of 306

Guidance and quality standards awaiting development
Title	Type
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]	Technology appraisal guidance
Aprocitentan for treating resistant hypertension [TSID10395]	Technology appraisal guidance
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia	Medical technologies guidance
Artificial intelligence technologies for mammography: early value assessment	Health technology evaluation
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance
Atrasentan for treating primary IgA nephropathy [ID6558]	Technology appraisal guidance
Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]	Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance